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1  | INTRODUC TION
Several kinds of trauma can trigger heterotopic calcification in soft 
tissues (trauma-induced calcification, TIC) involving the injury of the 
brain or the spinal cord, wounds, burn, bone fracture and orthopae-
dic operations or the combination of thereof. The calcification pa-
thology in a later stage usually results in the formation of mature 
lamellar bone in the extraskeletal tissues (heterotopic ossification, 
HO). These pathological calcifications cause complex clinical prob-
lems with no other intervention than anti-inflammatory medication 
and/or repeated surgical removal combined with radiation. The mo-
lecular and cellular events leading to HO are not understood in de-
tail; for a recent review, see Zhang et al.1
Formation of TIC and HO is associated with a systemic and local-
ized strong inflammatory response,2 the released cytokines trigger 
the differentiation of progenitor stem cells into osteoprogenitors 
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Abstract
Trauma-induced calcification is the pathological consequence of complex injuries 
which often affect the central nervous system and other parts of the body simulta-
neously. We demonstrated by an animal model recapitulating the calcification of the 
above condition that adrenaline transmits the stress signal of brain injury to the cal-
cifying tissues. We have also found that although the level of plasma pyrophosphate, 
the endogenous inhibitor of calcification, was normal in calcifying animals, it could 
not counteract the acute calcification. However, externally added pyrophosphate in-
hibited calcification even when it was administered after the complex injuries. Our 
finding suggests a potentially powerful clinical intervention of calcification triggered 
by polytrauma injuries which has no effective treatment.
K E Y W O R D S
animal models, bone-brain-nervous system interactions, disorders of calcium/phosphate 
metabolism, intervention, preclinical studies
11792  |     TŐKÉSI eT al.
and then the generation of new biomineral deposits and finally 
often new bone-like structures.3 The osteo-differentiation is man-
ifested in the dysregulation of several signalling networks, the major 
“player” is the bone morphogenic proteins (BMPs)-mediated path-
way; reviewed by.4 These regulatory effects lead to the activation of 
transcription factors as Sox-5, 6, 9, Runx2.5
In the present report, we focus on the typical case of a complex 
trauma-induced calcification when the patient suffers from both in-
jury of the central nervous system (CNS) and wound in the muscle 
(severe military, traffic or sport accidents; neurogenic heterotopic 
ossification).6 We have established an animal model with no calci-
fication when either trauma-induced brain injury or muscle damage 
was introduced separately, however, the simultaneous execution of 
the two resulted in massive calcification in the muscle. We investi-
gated the role of the sympathetic nervous system in transmitting the 
stress of the brain injury to the calcifying tissues. Furthermore, we 
have tested the effect of the inhibitory metabolite, pyrophosphate 
on the complex trauma-induced calcification.
2  | MATERIAL S AND METHODS
2.1 | Study approval and animals
The animal studies have been approved by the Ethical Committee of 
Animal Experiments, Governmental Office of Pest County, Hungary; 
No. PE/EA/280-7/2019 and were conducted according to the national 
guidelines. All animals were housed in approved animal facilities at the 
Research Centre for Natural Sciences, Hungarian Academy of Sciences. 
Mice were kept under routine laboratory conditions with 12-hour 
light-dark cycle with ad libitum access to water and chow. CD1 wild-
type female mice were obtained from Ttw+/− (kind gift of Prof. Frank 
Rutsch, University of Münster, Germany) mating and Enpp1+/+ geno-
type was confirmed in each animal. C57BL/6J mice were derived from 
the Department of Experimental Pharmacology, National Institute of 
Oncology, Hungary. Balb/C mice were obtained from the Immunology 
Department of Eötvös Loránd Science University, Hungary.
2.2 | Anaesthesia
Anaesthesia was carried out by intraperitoneal injection of the 
mixture of Zoletil (30 mg/kg, Virbac, France), Xilazin (12.5 mg/
kg, Produlab Pharma, The Netherland) and Butorfanol (3 mg/kg, 
Richterpharma, Austria).
2.3 | Traumatic brain injury (TBI)
Mice (24-32 g, female) were subjected to TBI in anaesthesia. A weight-
drop device was used to induce TBI as described.7 A weight (19 mm 
diameter, 95 g) of solid brass was utilized, a small steel cap (2 × 10 mm) 
was glued to the bottom of the weight to restrict the zone of contact 
to the top of the mouse head. Weight is dropped vertically through a 
guiding tube (20 mm diameter × 1.5 m length). The vertical traverse 
of the dropped weight is limited to ∼40 mm of impact displacement. 
A stage consisting of aluminium foil holds the animal in place. In this 
fashion, the foil supports the bodyweight with little resistance but 
upon impact (TBI) it breaks. The animals land on a sponge cushion.
2.4 | Cardiotoxin (CTX) injury
To induce muscle injury, immediately after TBI still in anaesthesia, 
mice (24-32 g, female) received a single injection of CTX into the 
hamstring muscle (0.12-0.16 mg/kg in 50 μL from a 12 μM solution 
of CTX; L8102, Latoxan, France; dissolved in sterile saline), which 
was delivered using a lateral approach using a 26G needle attached 
to an insulin syringe.
2.5 | Plasma adrenaline measurement
Plasma adrenaline level was measured by the Epinephrine/
Norepinephrine ELISA kit (KA1877, Abnova) according to the manu-
facturer's instructions. Blood was taken by cardiac puncture.
2.6 | Adrenaline and adrenaline-receptor antagonist
Adrenaline (Tonogen, Richter Gedeon, Hungary), 2 mg/kg, was injected 
intraperitoneally 5 minutes before CTX injection. Adrenaline-receptor 
antagonist prazosin (5 mg/kg, P7791, Sigma), yohimbine (1 mg/kg, 
Y3125, Sigma) and propranolol (3 mg/kg, P0884, Sigma) were dissolved 
in sterile saline and injected intraperitoneally 15 minutes before TBI.
2.7 | Histochemistry
Calcification of the muscle was visualized by Alizarin Red and von 
Kossa histochemistry following described methods.8
2.8 | CT scanning and analysis
CT measurements were performed on a NanoX-CT (Mediso, Hungary) 
cone-beam micro-CT imaging system. Circular CT scans were ac-
quired of two samples at a time with an 8W power X-ray source with 
55 kV tube voltage, 1.36 magnification, 900 ms exposure time, 1:1 bin-
ning and 360 projections in 7 minutes. For reconstruction, we used fil-
tered back projection with a Butterworth filter, and the isotropic voxel 
size was set to 70 μm. CT images were loaded into the open-source 
3D Slicer software9 (http://www.slicer.org), and a semi-automatic 
segmentation procedure was carried out to partition calcified tissue 
which has a signal intensity within the range induced by bone structure 
(maximum) and soft tissue (minimum). First, areas containing calcified 
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tissue were localized manually. Second, a local intensity threshold was 
applied to these areas to select the actual region of interest, but not 
the similar intensity noise from other regions of the image. As a final 
step, the volume of the segmented areas was measured, and a 3D 
model was created for visualization purposes with the built in tools 
of the software. For visualizing bone structures in the 3D figures, we 
used the volume rendering module of the software.
2.9 | Microcalcifications
Microcalcifications were characterized using Fourier transform in-
frared microspectroscopy (µ-FTIR). Tissue sections (4-µm) were 
deposited on low-emission microscope slides (MirrIR, Keveley 
Technologies, Tienta Sciences, Indianapolis). FTIR hyperspectral 
images were recorded with a Spectrum spotlight 400 FTIR imag-
ing system (Perkin Elmer Life Sciences, Courtaboeuf, France), with 
a spatial resolution of 6.25 micrometre and a spectral resolution of 
8 cm-1. Each spectral image covering a substantial part of the tissue 
consisted of about 30,000 spectra.
2.10 | Gene expression analysis
Total RNA was extracted from ∼30 mg muscle and liver tissues using 
TRIzol reagent (Thermo Fisher Scientific, MA, USA), and cDNA was 
synthesized using the SuperScript III First-Strand synthesis kit with 
random hexamers (Thermo Fisher Scientific, MA, USA). In each re-
action, 1 μg total RNA was used. The synthesis was performed as 
recommended by the manufacturer.
RT-qPCR was carried out using the Applied Biosystems 
StepOnePlus RT-PCR system and the Design Wizard StepOne 
software (Applied Biosciences Inc, CA, USA). Expression level of 
Abcc6 (Mm00497698_m1) and Enpp1 (Mm01193761_m1) in liver 
and Runx2 (Mm00501584_m1), Sox9 (Mm00448840_m1), Bmp-2 
(Mm01340178_m1) and Bmp-4 (Mm00432087_m1) in muscle was 
detected using commercially available TaqMan probes (Thermo 
Fisher Scientific, MA, USA). The expression level of Abcc6 and Enpp1 
in liver was normalized to beta2microglobulin (Mm00437762_m1). 
In muscle tissue, the expression level of four housekeeping genes: 
Gapdh (Mm99999915_g1), Actin-b (Mm00607939_s1), Hmbs 
(Mm01143545_m1) and ®2m(Mm00437762_m1) was found un-
stable between the different treatment groups, and therefore, they 
were not used as reference genes, rather we have normalized the 
obtained expression data to total amount of RNA.
2.11 | Pyrophosphate treatment and measurement
Mice received combined PPi treatment. On one hand, mice were 
treated with 80-100 mg/kg Na4P2O7 (71515, Sigma) dissolved in 
sterile saline via single daily intraperitoneal (IP) injections. The first 
IP was added right after TBI + CTX or ADR + CTX treatment, except 
in TBI + CTX+30 min PPi group, where it was added 30 min after 
TBI + CTX. Besides these IP injections, mice were simultaneously 
treated orally with PPi by changing their drinking water to 1 mM 
Na4P2O7 dissolved in distilled water after TBI. This combined PPi 
treatment was continued for 4 days. Control group received distilled 
water during the experiment. Determination of PPi concentration in 
plasma was performed as described in our previous paper.10
2.12 | Statistical analysis
Data were analysed by two-tailed Mann-Whitney non-parametric 
test. Values are expressed as mean and standard error of the mean 
(SEM). A P < .05 was considered statistically significant, and the 
actual p-values are indicated on the corresponding figures. Animal 
numbers used for individual data sets varied and are shown in the 
figures.
3  | RESULTS
3.1 | Combined traumatic brain injury and skeletal 
muscle damage (TBI + CTX), a model of neurological 
trauma-induced calcification
Spinal cord injury combined with skeletal (hamstring) muscle damage 
introduced by cardiotoxin injection has been described as an animal 
model of TIC.11,12 We have modified the original Genet-Torossian 
method and instead of trans-section of the spinal cord we have in-
troduced a mild mechanical (traumatic) injury of the brain (TBI),7 and 
combined this intervention with cardiotoxin-induced damage (CTX) 
in the hamstring muscle. We have observed no calcification when 
either TBI or CTX was introduced alone, however the simultaneous 
execution of the two insults resulted in massive calcification in the 
hamstring muscle, similar to the previously described, but more rad-
ical intervention. We have tested our novel approach (TBI + CTX) 
on three different mouse strains, C57Bl6, Balb/C and CD1. All three 
reacted unequivocally on the same manner: robust calcification in 
the injured hamstring muscle after four days of the combined in-
tervention. The calcification of CD1 animals (we used these animals 
in our further studies) was detected by micro-CT (Figure 1 panel 
A). Histochemistry of the hamstring muscle indicates strong Alizarin 
Red and von Kossa-positive calcified deposits (Figure 1, panels B 
and C, respectively).
3.2 | Expression of “calcification” genes in 
calcifying muscle
Next, we asked whether the trauma-induced calcification we are 
studying follows the usual route of the known osteo-differentia-
tion pathway. In order to answer this question, we have collected 
hamstring muscle samples from animals on days 1, 2, 3 and 4 after 
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TBI + CTX and compared the values to that of without TBI + CTX. 
We determined the expression level of genes Bmp2 and Bmp4, as 
well as Runx2 and Sox 9. In this experiment, we faced a technical dif-
ficulty: as we were studying heavily damaged tissue with dying and 
with de novo cells we could not use a reference gene (“housekeeping 
gene”), since the expression of Gapdh or Actin, or beta2microglobu-
lin, or Hmbs genes was not stable during the four days calcification 
period. Therefore, we have normalized the obtained expression data 
to total amount of RNA. The expression kinetics from all four genes 
showed a similar pattern: their abundance was barely detectable 
in control, non-injured animals and increased dramatically at day 1 
through day 4 (Figure 1D).
3.3 | Adrenaline mediates calcification
As muscle injury (CTX) without traumatic brain injury (TBI) did not 
trigger calcification in the injured muscle, we hypothesized that 
the reaction to the CNS-directed stress is transmitted through 
the sympathetic nervous system. Therefore, we wanted to test 
whether increased plasma level of adrenaline due to the CNS shock 
does play a role in “transmitting” the TBI stress to the injured mus-
cle. Indeed, we could measure a large increase of plasma adrenaline 
level 1 min. after TBI (see Figure 2, panel C). Then, we replaced TBI 
with injecting adrenaline intraperitoneally (ADR + CTX approach), 
2 mg/kg, 5′ before CTX. As a control, we have applied adrena-
line injection alone which resulted in no calcification in the ham-
string muscle (similar to the lack of effect of TBI alone, see above). 
However, ADR + CTX resulted in massive calcification to the same 
extent as TBI + CTX: 3.04 mm3 vs 5.31 mm3, the two data sets 
are not significantly different (see Figure 2. Panel A Images I and II 
and panel B). These results support that adrenaline plays a crucial 
role in the stress-mediated communication between CNS and the 
calcifying skeletal muscle.
3.4 | Effect of adrenaline-receptor antagonists
Next, we addressed the question: what is the target recep-
tor of the stress signal on the calcification pathway, and 
F I G U R E  1   Calcification of the 
hamstring muscle upon complex injury. 
Panel A: Representative micro-CT images, 
white arrows point to the calcified area 
(red). Panels B and C: Representative 
histochemistry of the calcified muscle 
from a TBI + CTX-treated animal: Alizarin 
Red staining for calcium (B) and von Kossa 
staining for phosphate (C). The white 
arrows point to the calcified tissue. Panel 
D: Expression kinetics of genes Bmp2, 
Bmp4, Runx2 and Sox9 upon trauma-
induced calcification in hamstring muscle
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therefore, we treated mice with adrenaline-receptor antago-
nists 15 min before TBI + CTX. We have injected yohim-
bine, an alpha2 receptor antagonist intraperitoneally (1 mg/
kg) and observed a massive inhibition of calcification com-
pared to the experiment without yohimbine (0 vs 5.31 mm 
calcified deposit in the hamstrings, P = .009, see Figure 2 
panel A , images I and III and panel B). These results point to 
alpha2 adrenergic receptor playing role in TBI-induced cal-
cification. Prazosin (5 mg/kg), an alpha1-receptor antagonist 
was not effective in halting TBI + CTX-induced calcification 
(5.31 vs 8.96, the two data set are not significantly differ-
ent, see Figure 2 panel A , images I and V and panel B). The 
beta-receptor antagonist propranolol (3 mg/kg) inhibited 
calcification (5.31 vs 0) on the same way as yohimbine (5.31 
vs 0 mm3 calcified deposit; see Figure 2 panel A , images I 
and IV and panel B.) The results of the experiments with 
adrenaline-receptor antagonists argue that alpha2 and beta-
adrenergic receptors play a role in TBI-induced calcification, 
while alpha1 receptor probably does not participate in trans-
mitting the stress signal.
3.5 | Neither plasma pyrophosphate level nor the 
expression of hepatic proteins controlling plasma PPi 
change upon TBI + CTX
As reduced plasma pyrophosphate level is the metabolic cause of 
inherited ectopic calcification disorders pseudoxanthoma elasticum 
(PXE) and generalized arterial calcification in infancy (GACI), we have 
supposed that reduction of PPi in plasma is the cause of TBI + CTX-
induced calcification too. To test this hypothesis, we have measured 
plasma pyrophosphate concentration in TBI + CTX (ie in calcifying 
animals) at 1, 2, 3 and 4 days and at 30′ after the combined trauma 
and compared the values to that of without TBI + CTX. We have 
observed that plasma PPi levels did not change significantly during 
calcification in the hamstring muscle (Figure 3, panel A).
The main source of circulating pyrophosphate is the liver and 
mutations in any of the two key proteins responsible for plasma PPi 
level, in ABCC6 or ENPP1 result in low level of plasma PPi. We have 
measured the expression of Enpp1 and Abcc6 genes in the liver of 
animals upon TBI + CTX at days 1, 2, 3 and 4 and compared the 
values to those of without TBI + CTX. We could not detect altered 
F I G U R E  2   Calcification of the 
hamstring muscle upon complex injury; 
effect of adrenaline and adrenaline-
receptor antagonists. Panel A: 
Representative micro-CT images, white 
arrows point to the calcified area (red). 
Panel B: Quantitative determination of 
the mineral deposits by micro-CT volume 
measurement. Panel C: plasma adrenaline 
concentration before (ctr) and 1 min after 
TBI
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expression of either Abcc6 or Enpp1 genes in the liver (Figure 3, pan-
els B and C). This finding is in harmony with the unaffected plasma 
pyrophosphate levels of these animals.
3.6 | Externally added pyrophosphate inhibits 
trauma-induced calcification
We found that normal level of plasma pyrophosphate is not suf-
ficient to counteract the rapid calcification due to the complex 
trauma, and therefore, we tested the effect of externally added 
pyrophosphate. Mice subjected to the TBI + CTX were put on 
combined PPi treatment: Addition of 1 mM Na4P2O7 in drinking 
water was combined with single daily intraperitoneal injections of 
Na4P2O7, 80-100 mg/kg for four days. The first IP injection was 
added right after TBI (within 1 min). This treatment resulted in a very 
effective inhibition of mineral deposition in the hamstring muscle 
(Figure 4 Panel A image I and II and Panel B): 5.25 mm3 vs 0.11 mm3 
with a p value of 0.02 (PPi in drinking water alone was not effective, 
not shown). This PPi treatment was found to be highly effective in 
inhibiting ADR + CTX-induced calcification too; 3.04 mm3 vs 0.09 
mm3, P = .03 (see Figure 4 Panel A image I. and III. and Panel B). 
This is similar to the effect of PPi on the TBI + CTX calcification (the 
two data sets are not different, P = .40). This finding supports that 
the step(s) of hydroxyapatite crystal formation inhibited by PPi is/are 
similar in the TBI and ADR-induced pathways.
As PPi is capable of inhibiting calcification, we raised the ques-
tion: can PPi be effective on the TBI + CTX-induced calcifica-
tion if the treatment is not started immediately after the injury? 
Therefore, we have applied the first intraperitoneal PPi injection 
30 min after the TBI + CTX injury, thus mimicking emergency in-
tervention after a severe traffic or combat injury. Otherwise, the 
PPi treatment was the same as above and continued for four days. 
We have observed a very effective inhibition of calcification, 5.25 
mm3 vs 0.08 mm3 with a p value of 0.03 (see Figure 4 Panel A image 
I and IV and Panel B). The microstructure of the mineral deposit 
in the pyrophosphate-treated animals was not different from that 
developed in non-treated animals (see Figure 4, panels C and D). It 
showed the typical composition of ectopic mineralization depos-
its: carbonated apatite with no octacalcium phosphate (OCP) and 
with low amorphous calcium-phosphate levels. It is obvious that 
PPi rather changes the volume and not the structure/composition 
of the mineral deposits.
4  | DISCUSSION
Pathological ectopic calcification of soft (connective) tissues is a 
major clinical problem, what is often associated with multi-traumatic 
injuries. The trauma involves a wide variation of impacts including 
injuries of the CNS, large burns, fracture of bones and major surgi-
cal interventions. It was recently demonstrated that deposition of 
hydroxyapatite within damaged skeletal muscle is sufficient to pre-
dispose skeletal muscle to HO indicating that dystrophic and het-
erotopic calcifications may be stages of a pathologic continuum.13 
Approximately, 90% of TBI patients with a fracture or dislocation 
of the elbow develop heterotopic ossification.14 The prevalence of 
calcification leading to severe heterotopic ossification is 64.5% in 
combat-related polytrauma injuries.15 Our in vivo model is based on 
a mild mechanical injury of the brain (TBI)7 combined with one of 
the most reliable muscle injury models resulting in pathophysiologi-
cal events that occur in human muscle, with the cardiotoxin-induced 
damage of hamstring muscle (CTX). We have observed calcification 
in the hamstring muscle only when TBI and CTX were introduced 
simultaneously. This observation supports that our animal model re-
capitulates the details of severe military-, traffic- or sport accident-
triggered neurological heterotopic ossification.6
We have asked the question: how stress is transmitted from the 
CNS to the calcifying tissue and found that adrenaline with concomitant 
F I G U R E  3   Plasma pyrophosphate level and expression of genes 
Abcc6 and Enpp1 in the liver during trauma-induced calcification. 
A: Plasma pyrophosphate level before (0) and at different time-
points after TBI + CTX. B and C: Expression of genes in the liver 
controlling plasma pyrophosphate level (B: Abcc6, C: Enpp1). 
Expression levels were normalized to that of beta2microglobulin
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CTX induces calcification in the injured muscle as effectively as the 
brain trauma indicating the role of the sympathetic nervous system in 
signalling. We have also found that adrenergic receptors alpha2 and 
beta are involved in the stress-mediated communication as pharmaco-
logical block of those receptors suspended the adrenaline-effect while 
alpha1 receptors seem not to be involved. The observation that block-
ing adrenergic receptors inhibits calcification suggested a therapeutic 
intervention using antagonists. However, we found no calcification 
inhibition if the alpha2 blocker yohimbine was added 30 minutes after 
the complex injury (10 mg/kg; not shown), this finding does not sup-
port an intervention based on adrenergic receptor blockage.
Up-regulation of transcription from the genes of the key pro-
tein components of tissue calcification, Bmp2, Bmp4, Runx2, Sox9 
was observed using qRT-PCR assay. All the above features indicate 
that the TBI + CTX polytrauma method triggers calcium-phosphate/
hydroxyapatite precipitation on the well-known inflammatory-os-
teo-differentiation pathway.
Our major finding was that externally added pyrophosphate, an 
endogenous inhibitor of hydroxyapatite formation 16 inhibits the 
complex trauma-induced calcification, even when it is added post-
trauma. It is worth to note that the microstructure of the mineral 
deposit in the pyrophosphate-treated animals was not different 
from that developed in non-treated animals (see Figure 4, panels C 
and D), that is PPi rather changes the volume and not the structure/
composition of the mineral deposits. PPi inhibits the ADR + CTX-
induced calcification in the same way, further supporting that the 
adrenaline-induced calcification is similar to that of the polytrau-
ma-induced calcification.
F I G U R E  4   Calcification of the 
hamstring muscle upon complex 
injury; effect of pyrophosphate. Panel 
A: micro-CT images, white arrow 
points to the mineral deposits (red). 
Panel B: quantitative determination 
of the mineral deposits by micro-CT 
volume measurement. Panel C and 
D: representative Fourier transform 
infrared microspectroscopy (μ-FTIR) 
spectra of microcalcifications of the 
hamstring muscle of a TBI + CTX animal 
(C) and a TBI + CTX animal treated 
with pyrophosphate (D). Green lines 
correspond to 1030 cm−1, the ν3 P–O 
stretching vibration mode of apatite
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Our next intention was to uncover the background of PPi ac-
tion. We could not detect significant change in the plasma PPi level 
during the 4-day period of calcification when the values were com-
pared to those prior polytrauma. The main source of plasma pyro-
phosphate is the liver, and the initial step is the ABCC6-facilitated 
release of trinucleotides, mostly ATP from hepatocytes. ATP is con-
verted promptly in the liver microcirculation to AMP and PPi by the 
ectonuclease, ENPP1.16,17 Mutations in any of the two key proteins 
result in decreased plasma PPi level, what is the metabolic cause of 
two monogenic inherited calcification diseases, pseudoxanthoma 
elasticum and generalized arterial calcification in infancy; for a re-
view, see Borst et al.18 We have determined the transcription from 
genes Abcc6 and Enpp1 in the liver by qRT-PCR before polytrauma 
and during the 4 days calcification and found no significant changes 
in the abundance of either mRNA (compared to the values obtained 
from livers before polytrauma treatment). These findings are in har-
mony with the observation of no significant change in the plasma 
PPi level during calcification. We can conclude that the key genes’ 
activities determining systemic PPi and the plasma PPi level itself are 
“normal”, that is not declined, and therefore, this can be ruled out as 
the cause of the polytrauma-induced calcification.
It has been shown long ago that the mechanism of PPi inhibitory 
action is based on blocking new calcium-phosphate crystal formation 
(ie de novo crystal formation) and also the growth of existing crystals 
by binding to the surface of hydroxyapatite,19,20 what is considered as 
the final common pathway in the pathophysiology of soft tissue calci-
fication. This is the “physico-chemical” effect of other polyphosphates 
too.21 It was also postulated that “it is apparently impossible for any 
calcification to occur in a system which contains a constant, physio-
logical concentration of inorganic pyrophosphate”.22 In contrast, our 
results argue that the physiological level of PPi in plasma upon trau-
ma-induced calcification does not suffice to prevent the massive and 
rapid hydroxyapatite formation in the damaged muscle in the acute 
situation. The benefit of increasing pyrophosphate level (directly or 
indirectly by modifying enzyme activities of generating or remov-
ing PPi) has been demonstrated in several animal models represent-
ing human diseases as PXE,10,23-25 as GACI,26 or Hutchinson-Gilford 
progeria syndrome.27 In each of the above cases, the low PPi level is 
the pathological cause of the calcification symptoms. However, trau-
ma-induced calcification is different as the externally added PPi does 
not substitute for the low level of this metabolite, it rather provides a 
highly elevated systemic PPi level what is able to counteract the rapid 
calcification triggered by the complex injury.
Trauma-induced calcification has no effective treatment. Our 
finding that pyrophosphate can prevent mineralization due to 
complex trauma—even when it was administered 30 minutes after 
trauma—raises the possibility of its therapeutical utilization. This 
encouraging result points to the potential of an “emergency” py-
rophosphate therapy to be executed shortly after the accident. 
Furthermore, pyrophosphate can be used as a preventive therapy 
adding prior to planned, large surgical interventions with the dan-
ger of heterotopic calcification and the treatment can be contin-
ued post-operation during recovery. The risk of pyrophosphate 
treatment is probably negligible as it is widely used as a food ad-
ditive and the Code for Federal Regulation by the FDA states: “This 
substance is generally recognized as safe”.
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